Mebendazole

Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration^[1][2][3]. IC50 & Target:Tublin polymerization^[1]; Hedgehog^[2]; Parasite^[3] In Vitro:Mebendazole (1 nM-0.1 mM; 72 h) shows inhibition of GL261 mouse glioma cells with IC value of 0.24 μM^[1].
Mebendazole (0.1 μM and 1 μM; 24 h) disrupts microtubule polymerization and microtubule structure in 060919 glioblastoma multiforme (GBM) cells^[1].
Mebendazole (10 nM-10 μM; 48 h) inhibits Hh signaling and reduces the expression of downstream Hh pathway effectors, by decreasing Gli1 transcript and protein expression in tumor tissues. Mebendazole inhibits Gli1 expression with an IC₅₀ value of 516 nM^[2].
Mebendazole (10 nM-10 μM; 48 h) prevents the formation of the primary cilium, and decreases the proliferation and survival of human medulloblastoma cells with constitutive Hh activation^[2].
A combination of mebendazole and Vismodegib (HY-10440) achieved additive inhibition of canonical Hh signaling^[2].
Mebendazole has effectively treated CNS echinococcosis in numerous clinical settings before, indicating significant CNS penetration property^[3].
In Vivo:Mebendazole (50 mg/kg; p.o.; once daily for first 20 d and 5 d per week with 2 d off; 45 d) inhibits intracranial tumor growth in the syngeneic GL261 mouse model and 060919 human glioblastoma multiforme (GBM) xenograft mouse model^[1].